179626-99-4

Basic information

• Product Name: 2-METHYL-4-PHENYL-8-QUINOLINOL
• Synonyms: 2-METHYL-4-PHENYL-8-QUINOLINOL
• CAS NO: 179626-99-4
• Molecular Formula: C₁₆H₁₃NO
• Molecular Weight: 235.28
• Mol File: 179626-99-4.mol

Chemical Properties

• Boiling Point: 401.1 °C at 760 mmHg
• Flash Point: 196.4 °C
• Appearance: /
• Density: 1.195 g/cm³
• Vapor Pressure: 5.21E-07mmHg at 25°C
• Refractive Index: 1.669
• CAS DataBase Reference: 2-METHYL-4-PHENYL-8-QUINOLINOL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYL-4-PHENYL-8-QUINOLINOL(179626-99-4)
• EPA Substance Registry System: 2-METHYL-4-PHENYL-8-QUINOLINOL(179626-99-4)

Safety Data

• Hazardous Substances Data: 179626-99-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H13NO/c1-11-10-14(12-6-3-2-4-7-12)13-8-5-9-15(18)16(13)17-11/h2-10,18H,1H3

Upstream product

• 35660-91-4 (E)-1-phenyl-2-buten-1-one 
• 95-55-6 2-amino-phenol 
• 495-41-0 1-phenylbut-2-en-1-one 

Relevant articles and documents

A New Series of Highly Potent Non-Peptide Bradykinin B2 Receptor Antagonists Incorporating the 4-Heteroarylquinoline Framework. Improvement of Aqueous Solubility and New Insights into Species Difference

Introduction of nitrogen-containing heteroaromatic groups at the 4-position of the quinoline moiety of our non-peptide B2 receptor antagonists resulted in enhancing binding affinities for the human B 2 receptor and reducing binding affinities for the guinea pig one, providing new structural insights into species difference. A CoMFA study focused on the diversity of the quinoline moiety afforded correlative and predictive QSAR models of binding for the human B2 receptor but not for the guinea pig one. A series of 4-(1-imidazolyl)quinoline derivatives could be dissolved in a 5% aqueous solution of citric acid up to a concentration of 10 mg/mL. A representative compound 48a inhibited the specific binding of [ 3H]BK to the cloned human B2 receptor expressed in Chinese hamster ovary cells with an IC50 value of 0.26 nM and significantly inhibited BK-induced bronchoconstriction in guinea pigs even at 1 μg/kg by intravenous administration.

Pyridopyrimidones, quinolines and fused N-heterocycles as bradykinin antagonists

This invention relates to a compound of the formula: STR1 wherein Z is a group of the formula: STR2 in which X1 is N or C--R1, X2 is N or C--R9, X3 is N or C--R2, R1 is lower alk